Antibiotic News and Research RSS Feed - Antibiotic News and Research

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.
Lymphatic pump treatment may fight pneumonia by enhancing efficacy of antibiotics

Lymphatic pump treatment may fight pneumonia by enhancing efficacy of antibiotics

Lymphatic pump treatment (LPT) shows promise in managing pneumonia when combined with antibiotic treatment, according to a new study published in The Journal of the American Osteopathic Association. [More]
New device can turn smartphone into DNA-scanning fluorescent microscope

New device can turn smartphone into DNA-scanning fluorescent microscope

If you thought scanning one of those strange, square QR codes with your phone was somewhat advanced, hold on to your seat. Researchers at the University of California, Los Angeles have recently developed a device that can turn any smartphone into a DNA-scanning fluorescent microscope. [More]
Papers on antibiotic resistance, neglected diseases and future of the ocean to be discussed during G7 summit

Papers on antibiotic resistance, neglected diseases and future of the ocean to be discussed during G7 summit

Today the national science academies of the G7 countries handed three statements to their respective heads of government for discussion during the G7 summit at Schloss Elmau in early June 2015. The papers on antibiotic resistance, neglected and poverty-related diseases, and the future of the ocean were drawn up by the seven national academies under the aegis of the German National Academy of Sciences Leopoldina. [More]
1 in 5 nursing home residents with dementia harbor strains of drug-resistant bacteria

1 in 5 nursing home residents with dementia harbor strains of drug-resistant bacteria

A new study found one in five nursing home residents with advanced dementia harbor strains of drug-resistant bacteria and more than 10 percent of the drug-resistant bacteria are resistant to four or more antibiotic classes. The research was published online today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. [More]
New WHO report analyzes global response to antimicrobial resistance

New WHO report analyzes global response to antimicrobial resistance

A quarter of countries that responded to a WHO survey have national plans to preserve antimicrobial medicines like antibiotics, but many more countries must also step up. A new report, "Worldwide country situation analysis: Response to antimicrobial resistance", which outlines the survey findings, reveals that while much activity is underway and many governments are committed to addressing the problem, there are major gaps in actions needed across all 6 WHO regions to prevent the misuse of antibiotics and reduce spread of antimicrobial resistance. [More]
New Johns Hopkins study finds occurrence of gonorrhea or chlamydia is significant in women

New Johns Hopkins study finds occurrence of gonorrhea or chlamydia is significant in women

Current public health guidelines recommend that only gay men and people with HIV should be routinely screened for extragenital gonorrhea and chlamydia, given the high burden of these sexually transmitted infections (STIs) in this at-risk population. [More]
Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex provides clinical trial update on ARIES HSV 1&2 Assay

Luminex Corporation today announced that testing at the clinical trial sites for the ARIES HSV 1&2 Assay is now complete. The next steps, including site to site reproducibility testing, followed by data analysis and assembly of the data package for submission to the FDA, are now underway. [More]
TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance. [More]
Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Preclinical data from Synthetic Biologics' SYN-005 for Pertussis treatment presented at ECCMID 2015

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented in two posters at ECCMID 2015 (European Congress of Clinical Microbiology and Infectious Diseases), on April 25, 2015, in Copenhagen, Denmark. [More]
U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

U-M study: Nearly half of American hospitals not taking key steps to prevent C. diff infections

Nearly half of American hospitals aren't taking key steps to prevent a kind of gut infection that kills nearly 30,000 people annually and sickens hundreds of thousands more - despite strong evidence that such steps work, according to a new study. [More]
Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis reports positive results from phase 3 study of single-dose DALVANCE for treatment of ABSSSI

Actavis plc today announced positive top-line results for study DUR001-303, a phase 3 study comparing a single 1500 mg dose of DALVANCE with the same total dose given as two-doses one week apart, for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin resistant Staphylococcus aureus (MRSA). [More]
Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

Leading scientists warn of 'Antibiotic Armageddon' in Britain and Europe by 2025

A group of leading scientists has warned that Britain and Europe collectively could face more than a million deaths in an impending "Antibiotic Armageddon” unless more is spent on developing new cures, rapid diagnostics and preventative measures to combat the spread of drug resistant diseases. [More]
Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

Findings suggest development of 'post-infection' vaccine to reduce TB rates in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
Alltech enters into agreement to acquire Ridley

Alltech enters into agreement to acquire Ridley

Alltech and Ridley Inc. announced today that they have entered into a plan of arrangement agreement under which Alltech will acquire 100 percent of the outstanding stock of Ridley, one of the leading commercial animal nutrition companies in North America, for CAD $40.75 per share. [More]
Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm announces initiation of Debio 1450 phase II study for treatment of ABSSSI

Debiopharm International SA, part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate Debio 1450 for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) due to Staphylococci, including all resistant Staphylococcus strains, tested so far. [More]
Rising shortages of key antibiotics raise serious concerns about effects on patient care

Rising shortages of key antibiotics raise serious concerns about effects on patient care

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Diseases and available online. The trends raise serious concerns about the effects on patient care, particularly for infections without effective alternative treatment options. [More]
Study finds increasing size of elderly population as major contributor to TB infection in China

Study finds increasing size of elderly population as major contributor to TB infection in China

A major contributor to the number of tuberculosis infections and cases in China will likely be the elderly over the next few decades, requiring a refocus in efforts to control a disease affecting millions of people in the country, according to preliminary new research presented today at the Fourth Global Forum on TB Vaccines in Shanghai. [More]
Gene therapy reduces infectious complications in children, teens with Wiskott-Aldrich syndrome

Gene therapy reduces infectious complications in children, teens with Wiskott-Aldrich syndrome

In a small study that included seven children and teens with Wiskott-Aldrich syndrome, a rare immunodeficiency disorder, use of gene therapy resulted in clinical improvement in infectious complications, severe eczema, and symptoms of autoimmunity, according to a study in the April 21 issue of JAMA, a theme issue on child health. [More]
Winners of GSA poster awards announced at Fungal Genetics Conference

Winners of GSA poster awards announced at Fungal Genetics Conference

The Genetics Society of America and the community of fungal geneticists are pleased to announce the winners of the GSA poster awards at the 28th Fungal Genetics Conference, which took place in Pacific Grove, CA, March 17-22, 2015. [More]
UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

UCLA-led stroke study selected as one of 10 most outstanding research papers by CRF

A UCLA-led study on improving stroke care was selected by the Clinical Research Forum (CRF) as one of the 10 most outstanding research papers written by teams from across the nation in 2014. The organization highlighted the papers at its fourth annual awards ceremony in Washington, D.C. on April 16. [More]
Advertisement
Advertisement